The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

UnitedHealthcare has agreed to a $2.5 million settlement in a class action lawsuit affecting just over 12,000 individuals. The lawsuit alleges UnitedHealthcare made unauthorized telemarketing calls in ...

Pennsylvania Governor Josh Shapiro signed into law Senate Bill 1232, which amended the Pennsylvania Workers’ Compensation Act ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application on track for a mid-2025 US launch. This positions it to compete effe ...

Earlier on Monday, Regeneron shared preliminary results from the fourth quarter that showed Eylea HD generated just $305 million in the U.S. It was a stunning drop-off from the $392 million the ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement ... Report on Form 10-Q for the third quarter ...

The stock has underperformed the sector and the S&P 500 Index during this timeframe. Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ sentiment.

Note: Another version of Eylea is available called Eylea HD. This is a higher dose, longer-acting form of the drug, and it’s used to treat wet AMD, diabetic retinopathy, and diabetic macular ...

Create forms, collect data, and analyse it easily with these platforms. All of the best online form builders we list below make it easy to collect customer feedback and marketing data with forms ...

Plaintiff pursues claims under Sections ... drug distributors in the form of reimbursed credit card fees. As a result, the DOJ alleges that the ASP of Regeneron’s Eylea drug was inflated ...